Remdesivir for Patients Hospitalized With COVID-19: Evidence of Effectiveness From Cohort Studies in the Omicron Era

Remdesivir is the only antiviral approved for treatment of persons hospitalized for coronavirus disease 2019 (COVID-19). This supplement presents new information from real-world cohort studies that report reduced mortality in at-risk populations and reduction in readmission for COVID-19 in the Omicron era.